Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • About us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • What’s next?
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
      • Job opportunities
    • Support Us
    • Keep in touch
    • Our annual accounts
  • Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Become a Corporate Charity Partner
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

2008 prostate colloquium

“Image-directed therapy for prostate cancer – the challenges ahead.”

In May 2008 an international group of surgeons, radiologists, oncologists, scientists and patient representatives met to discuss tumour imaging as an accurate means of characterising and mapping the true volume and extent of prostate cancer. They concluded that contemporary tumour imaging technologies have the potential to change the way prostate disease is both evaluated and treated.

The meeting received reports of research from the UK, the USA and France that identify 1.5T magnetic resonance imaging (MRI) as currently the most effective and widely available imaging method to detect, pin-point and help quantify tiny zones of cancerous tissue in the prostate.

According to meeting chairman, Mr Mark Emberton (now Professor Emberton), Reader in Interventional Oncology, University College London (UCL), non-invasive imaging could help cut down on repeated tissue biopsies, prevent over-aggressive surgical approaches to treatment and so help reduce much of the unnecessary morbidity associated with current prostate cancer surveillance and management.

The meeting delegation plans to form a steering group to help integrate imaging into the routine clinical management of prostate cancer. This led to the PROMIS trial – link to UKCRN page. It believes that a programme of clinical research, together with educational guidance and support for standardised reporting of imaging data, will allow prostate tumour imaging to play a major part in cancer management.

Other papers on the various challenges and therapies involved in treating prostate cancer were presented. The group also discussed staging and distinguishing between men with advanced disease and those with low volume, non-metastatic disease, is how best to manage patients with low volume disease.

Options for treatment such as focal therapy, a move away from radical therapy, that will ablate only parts of the prostate considered affected by clinically significant cancer, or active surveillance – involving regular assessments and tests for disease progression. Focal therapy ablates discrete areas of known cancer in the prostate and can offer men a treatment option to control disease while preserving maximal amounts of healthy tissue

 

Final Report:

    • Final Report Pelican Prostate Colloquium 2008

Other Presentations:

  • Focal Therapy Hashim Uddin Ahmed
  • HIFU Hashim Uddin Ahmed
  • MRI Urologists Perspective
  • MRI Mark Emberton
  • Other Modalities Rowland Illing
  • Prostate MRI – Against the motion Dr Aslam Sohaib
  • Photodynamic Therapy Ms Caroline Moore
  • Global Treatment Omar Karim

Other Papers:

  • Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy Rowland O. Illing, Tom A. Leslie, James E. Kennedy, Jogn G. Calleary, Christopher W. Ogden, Mark Emberton, 2006 BJU International 98, pp 1187-1192
  • `To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?` Toyoaki Uchida, Rowland O. Illing, Paul J. Cathcart, Mark Emberton, 2006 BJU International, 98, pp 537-539
  • The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy Toyoaki Uchida, Rowland O. Illing, Paul J. Cathcart, Mark Emberton, 2006 BJU International, 98, pp 770-772
  • `How Good is MRI at Detecting and Characterising Cancer within the Prostate?` Alexander P.S. Kirkham, Mark Emberton, Clare Allen, European Eurology 50 (2006), pp 1163-1175.
  • Letter in response to: Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic Contrast Enhanced, Pelvic Phased Array Magnetic Resonance Imaging of Lolcalized Prostate Cancer for Predicting Tumour Volume: Correlation with Radical Prostatectomy Findings. Ahmed HU, Illing RO, Calleary J, Arya M, Allen C, Emberton M. J UROL 176: 2432-2437, 2006.

Pelican Cancer Foundation Follow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican_Cancer
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
8 Feb

Excited to be holding our 5th annual workshop for Bowel Cancer Screening Practitoners.

Reply on Twitter 1623258266829455362 Retweet on Twitter 1623258266829455362 1 Like on Twitter 1623258266829455362 5 Twitter 1623258266829455362
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
28 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1597119096096784384 Retweet on Twitter 1597119096096784384 2 Like on Twitter 1597119096096784384 2 Twitter 1597119096096784384
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
26 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1596393313757642752 Retweet on Twitter 1596393313757642752 1 Like on Twitter 1596393313757642752 1 Twitter 1596393313757642752
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2023 · Outreach Pro Theme on Genesis Framework · WordPress · Log in